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Abstract
Background: HIV infection is reported to be associated with some malignant lymphomas (ML) so
called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis. The ML
frequency, pathogenicity, clinical patterns and possible association with AIDS in Tanzania, are not
well documented impeding the development of preventive and therapeutic strategies.
Methods: Sections of 176 archival formalin-fixed paraffin-embedded biopsies of ML patients at
Muhimbili National Hospital (MNH)/Muhimbili University of Health and Allied Sciences (MUHAS),
Tanzania from 1996–2001 were stained for hematoxylin and eosin and selected (70) cases for
expression of pan-leucocytic (CD45), B-cell (CD20), T-cell (CD3), Hodgkin/RS cell (CD30),
histiocyte (CD68) and proliferation (Ki-67) antigen markers. Corresponding clinical records were
also evaluated. Available sera from 38 ML patients were screened (ELISA) for HIV antibodies.
Results: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was
4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and
22.16% Hodgkin's disease (HD). The ML tumors frequency increased from 0.42% (1997) to 0.70%
(2001) and 23.7% of tested sera from these patients were HIV positive. The mean age for all ML
was 30, age-range 3–91 and peak age was 1–20 years. The male:female ratio was 1.8:1. Supra-
diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-
cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central
nervous system lymphoma (PCNSL) were diagnosed.
Conclusion: Malignant lymphomas apparently, increased significantly among diagnosed tumors at
MNH between 1996 and 2001, predominantly among the young, HIV infected and AIDS patients.
The frequent aggressive clinical and histological presentation as well as the dominant B-
immunophenotype and the HIV serology indicate a pathogenic association with AIDS. Therefore,
routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable
comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.
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Background
After a long asymptomatic period of variable duration,
HIV infection results in lowered immunity with increased
susceptibility to new and/or normally latent infections
and opportunistic tumors characteristic for the late stage
called acquired immune deficiency syndrome (AIDS).
Depending on the region, 25–40% of HIV-1 seropositive
patients eventually develop a malignancy predominantly
Kaposi's sarcoma (KS) and malignant lymphoma (ML)
mostly sub-classified as non-Hodgkin (NHL) [including
Burkitt's lymphoma (BL)] and Hodgkin's lymphoma
(HL) also known as Hodgkin's disease (HD) which were
shown to increase with the HIV epidemic in the USA. [1,2]
In Tanzania a higher proportion of NHL has been
reported [3] during the AIDS epidemic as shown by a fre-
quency of 9.1% in males in Dar es Salaam (1990–91)
compared to the 6.3% during 1980–81 pre-AIDS period.
[4] Corresponding figures for females during the same
time periods were 3.5%. Reported data from Uganda
showed an increase in age standardised rates (ASR) for
NHL for the periods 1954–60 and 1993–97 of 3.2 to 5.7
for males and 2.9 to 4.2 per 100,000 for females. [3] Rare
ML subtypes namely primary effusion lymphoma (PEL)
or body cavity-based lymphoma (BCBL) as well as pri-
mary central nervous system lymphoma (PCNSL) are also
more often associated with AIDS. [5,6] ML occurring in
HIV infected persons are called AIDS-related lymphomas
(ARL) and have distinct clinical and pathogenetic charac-
teristics including, extra-nodal presentation, systemic dis-
semination, B-cell phenotype, presence of Epstein-Barr
virus (EBV) markers in tumor cells and recurrent genetic
lesions. [6-8] About 70–90% of ARL are predominantly
high-grade diffuse large cell (DLBCL) having poor prog-
nosis. [9] A similar entity has also been described in exper-
imental simian AIDS-related lymphomas (SARL). [7]
Although it is not regarded as an AIDS-defining malig-
nancy, HD appears also to occur more commonly in asso-
ciation with AIDS particularly the mixed cellularity (MC)
and lymphocyte depletion (LD) subtypes [10-13] and to
have clinico-biological features similar to those of AIDS-
related NHL. [6,11] It appears that HIV infection alters the
clinical course of HD and therefore advanced or high-
grade HD in HIV-infected individuals should be consid-
ered indicative of AIDS. [13]
Burkitt's lymphoma, first described in Africa by Dennis
Burkitt in 1958, is a B-cell neoplasm and the commonest
childhood tumor in equatorial Africa. [14,15] The inci-
dence of BL in North Mara, Tanzania from 1964 to 1970,
was 5.7/100,000 being higher in males than in females.
[16] An incidence of BL in Kilimanjaro (high altitude)
region was found to be 1.4/100,000 for boys and 0.7/
100,000 for girls aged 5–9 years for the period 1971–
1980. [17] This study revealed geographical variations
that were related to altitude as was also shown by the pro-
portional ratios for BL of 11.8% of tumours in North Mara
[18] and of 21.6% in males in Tanga (both low altitude
areas). [19]
Surprisingly however, an increased incidence of ARL has
so far not been consistently observed in other regions of
Africa. However, the association of NHL, HD and BL with
HIV and AIDS generally in Africa including Tanzania is
poorly documented and needs further clarification.
[20,21]
Methods
Study area
The equatorial East African country of Tanzania has a pop-
ulation of approximately 35 million with roughly a 1:1
male: female ratio (National Bureau of Statistics, 2002).
HIV serology
Evaluation of HIV-1 infection (by ELISA) was performed
at the Microbiology/Immunology department at Muhim-
bili University of Health and Allied Sciences (MUHAS) as
previously described. [22]
Biopsies
Archival formalin-fixed paraffin-embedded (FFPE) diag-
nostic ML tissue biopsies (176) delivered to the Histopa-
thology Laboratory, Muhimbili National Hospital
(MNH), Dar es Salaam from 1996 to 2001 were reassessed
and selected (based on quality and amount of tissue mate-
rial/block) ML biopsies (70) were immunoassayed. Corre-
sponding clinical files and histological reports were also
retrieved.
Histology and immunohistochemistry (IHC)
This was done at the Department of Histopathology and
Morbid Anatomy (MNH/MUHAS). Briefly, tissue sections
(5 μ thick) were stained with Hematoxylin and Eosin (H
& E) as previously described.[12,22]
For IHC the avidin-biotin complex (ABC) immunoperox-
idase technique was used as previously described [12,22]
on tissue sections, mounted on SuperFrost® slides (Menzel
GmbH & Co KG, Braunschweigh, Germany) deparaffin-
ized, rehydrated and boiled in a microwave for 6 minutes
in citrate buffer at pH 6 and 750W for antigen retrieval.
Quenching of endogenous peroxidase activity, was done
by incubating the sections in 30% hydrogen peroxide in
distilled water for 30 minutes at room temperature, wash-
ing in Tris-buffered saline (TBS) followed by incubating
with 1:20 normal serum from the species providing the
secondary antibody and washed (TBS). The sections were
then incubated overnight at 4°C with the respective pri-
mary antibody (diluted 1:50) including respectively,
mouse monoclonal to pan-leucocyte anti-human CD45Journal of Experimental & Clinical Cancer Research 2008, 27:9 http://www.jeccr.com/content/27/1/9
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(clone LCA), B-cell anti-human CD20 (clone L26), mac-
rophage anti-human CD68 (clone Kp-1), the anti-human
Ki-67 (MIB-1) proliferation marker or the rabbit polyclo-
nal anti-human CD3 (T-cell) marker all anti-mouse/rab-
bit antibodies from DakoCytomation, (Glostrup,
Denmark). Subsequently, the sections were rinsed with
buffer and incubated with ABC, washed and developed
(visualized) with Sigma DAB chromogen (Sigma-Aldrich,
St. Louis MO, USA) as previously described [12,22] and
after TBS washing, lightly counter-stained with Harris
Hematoxylin, blued in running tap water for 30 minutes,
dehydrated in ascending grades of ethanol, cleared in two
runs of xylene and mounted with DPX and coverslipped.
Negative controls included sections from tissues not
expressing the respective antigen as well as substitution of
the primary antibody by buffer. Positive controls included
tissue sections known to express the antigen under inves-
tigation.
Microscopic evaluation
Sections were analyzed using a Carl Zeiss axiomatic phot-
omicroscope (Jena, Germany). Cell reactivity was
expressed as mean positive cells/total number of cells in 8
high (× 400) power fields (HPF). Picture processing and
printing was done using Adobe Photoshop 7.0 (Adobe
Systems Incorporated, San Jose, USA) and Microsoft-
Power Point 2003 (Microsoft Corporation, Redmond,
WA, USA).
Statistical analysis
The coded results were analyzed in a PC computer using
the EPI INFO 6 statistical software (CDC, Atlanta, Geor-
gia, USA). P-values of ≥ 0.05 were considered statistically
significant.
Ethical considerations
A strictly confidential specimen processing and evaluation
was conducted. HIV screening was performed upon
informed consent in the respective wards and clinics at
MNH and the study was conducted after appropriate
review by MUHAS Institutional Review Board (IRB) and
Ethical Clearance, under the TANSWED HIV Project E.
Results
General demography and ML frequency
Out of a total of 4200 diagnosed tumors 176 ML (4.2%)
were consecutively collected at MNH during the 1996–
2001 period. Of these, 112 (63.6%) were males and 64
(36.4%) females corresponding to a male:female (M:F)
ratio of 1.8:1 (Table 1). Age data was available for 171
cases and the mean and median ages at diagnosis for those
ML were 30.23 and 25.00 years respectively (standard
deviation [SD] = 21.45) and the age range was 3–91 years,
(Table 1). Of the total ML, 59 were NHL, 19.0% BL (34)
and 22.0% HD (39) [Figure 1]. It appears that ML
increased from about 0.42% in 1997 to 0.70% in 2001
largely due to cases of NHL (2.0–3.7%) and HD (0.6–
1.3%) whereas the incidence of BL remained constant,
which differences were statistically highly significant (p-
value = 0.001) [Figure 2].
Non-Hodgkin's lymphoma (NHL)
The age range for NHL was 4–91 years with a mean and
median age of 42 and 39.01 years respectively (Table 1)
and more males (64.08%) were affected by NHL (66/103)
than females (35.92%, 37/103) but the distribution of
NHL histological subtypes with sex was not significantly
different (p = 0.23) [Table 2]. High-grade NHL [Figure
3(a)] accounted for 62.14% (64/103) of total NHL while
low-grade histological types [Figure 3(b)] accounted for
37.86% (39/103) [Table 2]. The age ranges for high-grade
NHL (HGNHL) and low-grade NHL (LGNHL) were 14–
76 and 4–91 years and the mean age 36.06 and 44.11
years respectively, which differences were highly statisti-
cally significant (p-value = 0.0036) [Table 2].
Hodgkin's disease (HD)
Over half of the HD cases (51.30%, 20/39) were of mixed
cellularity (MC) histology [Figure 3(c)] followed by the
nodular sclerosing (NS) (25.6%, n = 10/39) and lym-
phocyte predominance (LP) (15.4%, n = 6/39) subtypes.
There was only one case of lymphocyte depletion (LD)
subtype in the material (Table 2). The age range for HD
was 5–70 and the mean age 26.42 years (Table 1). The age
ranges for HD according to subtypes were 11–51, 7–57,
and 5–41 years for LP, MC and NS respectively. The mean
Table 1: Frequency of ML at MNH by age, sex and HIV serostatus
DIAGNOSIS AGE (Years) SEX [NO (%)] HIV SEROSTATUS [NO (%)] TOTAL
MIN MAX MEAN M:F Ratio Positive Negative Tested Not-tested NO (%)
NHL 4 91 39.01 66(64.1)/37(35.9) = .1.8:1 5 (25.0) 15 (75.0) 20 (19.4) 83 (80.6) 103 (58.52)
HD 5 70 26.42 25(64.1)/14(35.9) = 1.8:1 4 (28.6) 10 (71.4) 14 (35.9) 25 (64.1) 39 (22.16)
BL 3 20 8.94 21(61.8)/13(38.2) = 1.6:1 0 (0.0) 4 (100.0) 4 (11.8) 30 (88.2) 34 (19.32)
NHL+HD+BL 4 91 30.23 112(63.6)/64(36.4) = 1.8:1 9 (23.7) 29 (76.3) 38 (21.6) 138 (78.4) 176 (100.0)Journal of Experimental & Clinical Cancer Research 2008, 27:9 http://www.jeccr.com/content/27/1/9
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ages were 34.20, 24.32 and 23.00 years for LP, MC and NS
respectively and the patient with LD was 70 years old
(Table 2).
Burkitt's lymphoma (BL)
The age range for BL cases [Figure 3(d)] was 3–20 years
and the mean and median ages were 8.94 and 7.00 years
respectively (Table 1). A male preponderance (61.8%, 21/
34) for BL over females (38.2%, 13/34) was highly statis-
tically significant (p-value < 0.0001) (Table 1).
HIV association of lymphomas
Only 21.6% (38/176) of the ML patients were available
for testing by serology for HIV infection during the study
period and nine (23.7%) tested positive including five
(55.6%) NHL (all B-cell type), and four (44.4%) HD
while all screened BL (4) were seronegative (Table 1 and
Figure 4). Most seropositive NHL (80%, n = 4/5) were
high-grade and of B-cell phenotype (see below) although
this was not statistically significant (2-tailed p-value =
0.6126, Fisher Exact test) [Table 3]. No correlation of HD
histological subtypes with HIV was statistically significant
(Table 1).
Clinical presentation
Most (65.3%) ML patients (115/176) had localized
tumors but disease dissemination increased significantly
with age, p-value = 0.038. More (58.5%) patients (n =
103/176) presented primarily with supra-diaphragmatic
than sub-diaphragmatic ML which difference was statisti-
cally highly significant (p-value < 0.0001). Most of the
HIV seropositive ML (66.7%, n = 6/9) had generalized dis-
ease (χ2 = 21.06, p-value = 0.00031) and either isolated
supra-diaphragmatic (66.7%, n = 6/9) or bi-diaphrag-
matic but not isolated sub-diaphragmatic disease (p-value
= 0.00039).
Immunohistochemistry
Immunohistological reactivity for the various antigens
studied are summarized in table 4 and illustrated on fig-
ures 5(a–d). All stained BL (15/34) and NHL (40/103)
cases and some cells in stained HD biopsies (15/39)
showed reactivity for leucocyte common antigen (CD45;
LCA), and the B-cell antigen (CD20) [Figure 5(a)]. The
LCA and CD20 reactivity was localized on cell membranes
and diffusely dispersed within the tumour tissue. More
than 90% of the tumor cells showed reactivity indicating
a lymphocytic B-cell lineage. T-cell (CD3) and macro-
phage antigens (CD68) [Figure 5(b) &5(c)] were
expressed on tumor infiltrating T-cells and macrophages
in variable frequency with cases suggesting varying
inflammatory/immunological reactivity to the tumor
cells. HD cases showed variable immunoreactivity on the
Pie chart showing the proportion of different ML types at  MNH between 1996 and 2001 Figure 1
Pie chart showing the proportion of different ML types at 
MNH between 1996 and 2001. Note that NHL formed the 
largest group.
Distribution of ML major histological types at MNH between 
1996 and 2001 
BL
19%
HL
22%
NHL
59%
BL
HL
NHL
Table 2: Distribution of ML histological subtypes by sex and age
HISTOLOGY MEAN AGE (Years) SEX [NO (%)] TOTAL
NHL Male/Female M:F Ratio
LGNHL 44.1 30(76.9)/9(23.1) 3.3:1 39 (23.4)
HGNHL 36.0 37(57.8)/27(42.2) 1.4:1 64 (70.3)
TOTAL NHL 67(65.1)/36(34.9) 1.9:1 103 (100.0)
HD
LP 34.2 3(50.0)/3(50.0) 1:1 6 (15.4)
LD 70.0 0/1(100.0) N/A 1 (2.56)
MC 24.3 12(60.0)/8(40.0) 1.5:1 20 (51.3)
NS 23.0 8(80.0)/2(20.0) 4:1 10 (25.6)
NOS* 2(100.0)/0 N/A 2 (5.1)
TOTAL HD 25(64.3)/14(35.7) 1.8:1 39 (100.0)
*Not Otherwise SpecifiedJournal of Experimental & Clinical Cancer Research 2008, 27:9 http://www.jeccr.com/content/27/1/9
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cells for LCA and CD20 depending on the histological
type but the RS cells were not reactive to CD20. CD3 and
CD68 expressions were focal but variable depending on
the histological subtype (Table 4). Variable expression of
nuclear Ki-67 was seen in lymphomas and included a
mean positive cell/HPF of 70.0% for BL, 40.0% for NHL
and 25.0% in HD [Figure 5(d)].
Concordance between clinical and histological diagnosis at 
MNH
A clinical diagnosis of ML was available in only 117 of the
176 (66.5%) cases studied. The overall concordance
between the clinical and histological diagnosis of ML was
62.4% (n = 73/117). Unexpectedly, concordance was
highest for HD (76.9%, n = 20/26) than BL (47.8%, n =
11/23) although the latter may seem easier to diagnose
clinically because of the characteristic age and anatomical
presentation but these variations were not statistically sig-
nificant, p-value = 0.1091.
Discussion
The combined frequency of major types of ML in the cur-
rent tumor biopsy study in Tanzania (4–5%) is generally
comparable to that reported in developed countries
including a range of 2.9–4.9% in the USA and about 3.5%
in Europe. [1,23,24] This is interesting considering the
fact that an increasingly major influence in African ML
pathogenesis is supposedly HIV and AIDS whose epi-
center is in sub-Saharan Africa which includes Tanzania.
[25,26] Furthermore, racial and geographic differences are
also known to contribute to ML distribution globally.
[24,27] This global similarity, could however, in part be
explained by the ubiquitous distribution of EBV which is
also considered a major ML pathogen. [27,28] Although
this study is hospital-based allowing an insight into ML
frequency at MNH, it is not sufficient to offer a solid basis
for comparison with other countries.
The apparent increase in frequency of total ML between
1997 and 2000 appears largely to be contributed by NHL
as well as HD but not BL which is in agreement with our
previous report of increasing ML frequency in the early
1990's (2nd post-HIV) decade [12] and indicating a role of
the HIV and AIDS epidemic as also reported elsewhere.
[12] That NHL had a leading frequency followed by HD
and BL is largely in agreement with reports from other
studies including a previous Tanzanian report [29] and an
East Malaysian study. [30] Conversely, an MNH study
from the pre-HIV epidemic era of a cervical lymphaden-
opathy pediatric series indicated a higher (34.5%) fre-
quency of HD relative to NHL. [31] These studies together
support the notion that HIV and AIDS influence the fre-
quency and distribution of lymphomas worldwide
including the fact that some ML are strongly associated
with AIDS and/or may be AIDS-defining. [2,6,12] These
results however, are not inline with the low (≈20%) HIV
frequency observed in the current lymphoma cohort due
to the rather sparse HIV screening of ML at MNH which
does not allow definitive evaluation of ARL in Tanzania.
Despite this fact however, it is noteworthy that a slight
majority (55.6%) of NHL and a significant proportion
(44.4%) of HD tested were HIV seropositive suggesting an
Frequency polygon showing variation of different ML types with time at MNH between 1996 and 2001 Figure 2
Frequency polygon showing variation of different ML types with time at MNH between 1996 and 2001. Note the increase in 
frequency of NHL and HD between 1997 and 2000.
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increased ML association with the AIDS epidemic among
the biopsies submitted at the hospital during the study
period.
The male predominance for ML in this study, compares
more with a Pakistan study (ratio 1.9:1) [32] than with a
report from neighboring Kenya (ratio 1.2:1) which is sur-
prising. [33] However, the reasons for a lower M:F ratio in
Kenya than in Tanzania are not clear but they may include
differences in hospital seeking behavior or under-report-
ing in Kenya. Considering that all ML subtypes showed
male preponderance it is not clear whether differences in
(a) H & E section of a diffuse large cell lymphoma (DLBCL) [high grade NHL]; note the high mitotic index [blue arrows] (×  400) Figure 3
(a) H & E section of a diffuse large cell lymphoma (DLBCL) [high grade NHL]; note the high mitotic index [blue arrows] (× 
400). (b) H & E section of a small cell lymphoma [SCL] which is a low-grade NHL (× 400). (c) H & E section of a Hodgkin's dis-
ease mixed cellularity (HDMC) case; note the classical Reed-Sternberg (R-S) cell [blue arrows] and eosinophil cells [black 
arrows] (× 400). (d) H & E section of a BL; note the "starry-sky" appearance due to tingible-body macrophages [black arrows] 
(× 200).
Table 3: Distribution of HIV antibody serostatus by histological grade of NHL at MNH (1996–2001)
GRADE
HIV SEROSTATUS LGNHL HGNHL TOTAL NO (%)
POSITIVE 1 (20.0%) 4 (80.0%) 5 (29.4%)
NEGATIVE 6 (40.0%) 9 (60.0%) 15 (70.6%)
TOTAL 7 (35.0%) 13 (65.0%) 20 (100.0)
2-Tailed p-value = 0.6126 (Fisher Exact Test)Journal of Experimental & Clinical Cancer Research 2008, 27:9 http://www.jeccr.com/content/27/1/9
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sex, biological pathogenesis and/or yet unclear socio-
environmental factors influence this distribution
although a selection bias and differences in hospital seek-
ing behavior between sexes could also be considered.
The age distribution of the studied Tanzanian ML cohort
as well as of the NHL cases appears similar to that reported
in studies from neighboring Kenya and Uganda as well as
Pakistan. [32-34] Likewise, the peak age for BL patients in
our study is concordant to that reported in Kenya [15] and
elsewhere. [14,20] Unexpectedly however, HD cases in
our current study did not show the usual clear bimodal
age pattern although the mean age of 26 years was con-
cordant with that reported in a previous Ugandan study.
[34] Apparently, the mean age in our series and the Ugan-
dan study indicate that East African HD presents at a con-
siderably younger age than that reported in USA (≈33
years) and Taiwan (41.5 years) [13,34,35] The reasons for
the differences are not clear although these may include
age-related oncogenic factors, geographical and other
environmental factors as well as the influence of HIV
infection in sub-Saharan Africa, considering the above-
stated proportion of HIV infected HD patients at MNH in
our current study. [24] Reports show that childhood HD
occurs at a younger age in various countries with limited
resources than in western countries. Thus as many as 20 to
30% of childhood HD cases in developing countries occur
before 5 years of age against some 5% in industrialised
countries. [36,37] Furthermore, it is reported that there is
an inverse relationship between the incidence of the HD
in children and young adults within countries according
to their economic development. [37] Low socio-economic
status may generate malnutrition, which could lead to
impaired immunity after initial exposure, and so to devel-
opment of HD. [37]
The HGNHL (B-cell type) association with HIV in the cur-
rent study was expected and is consistent with previous
reports. [9,33] However, the well known ARL including
PEL and PCNSL were not found in the present cohort
probably due to inadequate clinical surveillance for them
(including pleural biopsies and cerebro-spinal fluid (CSF)
cytology). Our finding that MC was the most frequent HD
subtype is consistent with other reports. [38] Further-
more, the MC subtype has also been found to be most fre-
quent in the setting of HIV and AIDS. [11,13] Considered
together these reports and our current study suggest that,
the presentation of HIV-associated HD is different from
that which is not HIV associated. [6] An association
between BL and HIV could not be established in the cur-
rent study due to rather small numbers of tested patients
who were all seronegative. However, BL has been shown
to be associated with HIV in other studies. [39,40] Note-
worthy also, was that most NHL seropositive for HIV in
the current study presented with generalized lymphaden-
opathy, apparently indicating a more aggressive clinical
course as compared to the non-HIV associated ML. Recent
studies have also reported a correlation between HIV
Pie chart showing the proportion of ML serologically  screened for HIV antibodies at MNH between 1996 and  2001 Figure 4
Pie chart showing the proportion of ML serologically 
screened for HIV antibodies at MNH between 1996 and 
2001. Note that a large number of ML at MNH were not 
screened for HIV.
HIV Serology for Lymphomas at MNH between 1996 
and 2001
Positive
5% Negative
16%
Untested
79%
Positive
Negative
Untested
Table 4: Immunohistochemical characteristics of ML at MNH
IMMUNOREACTIVITY FOR:
TUMOUR LCA* CD20 CD3 CD68 MEAN Ki-67 (% 
+/HPF)
BL Reactive (membranous 
cytoplasmic) in all tumour 
and infiltrating cells
Reactive (membranous 
cytoplasmic) in all tumour 
cells
Focal (membranous 
cytoplasmic) reactivity in 
infiltrating T-cells
Focal (membranous 
cytoplasmic) reactivity in 
infiltrating phagocytes
70.0
NHL Reactive (membranous 
cytoplasmic) in all tumour 
and infiltrating cells
Reactive (membranous 
cytoplasmic) in all tumour 
cells
Focal (membranous 
cytoplasmic) reactivity in 
infiltrating T-cells
Focal (membranous 
cytoplasmic) reactivity in 
infiltrating phagocytes
40.0
HD Reactive (membranous 
cytoplasmic) in all tumour 
and infiltrating cells
Focal reactivity in 
infiltrating B-cells while RS 
and Hodgkin cells negative
Focal reactivity in 
infiltrating T-cells
Focal (membranous 
cytoplasmic) reactivity in 
infiltrating phagocytes
25.0
*LCA: Leucocyte common antigen (CD45)Journal of Experimental & Clinical Cancer Research 2008, 27:9 http://www.jeccr.com/content/27/1/9
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infection and disseminated ML with lymphadenopathy,
scalp and bone marrow involvement (anatomical distri-
bution) and pancytopenia. [33,41]
The Ki-67 immunoreactivity (cell proliferation) seen
among BL, NHL and HD cases at MNH is comparable
with that in other reports [42,43] but the value of such
proliferation markers like Ki-67 and cyclin-A (Cy-A) as
prognostic indicators in Tanzania needs extended studies.
Although reasonable concordance was observed between
clinical and histopathological diagnosis of ML at MNH,
further diagnostic improvements are needed to allow an
international comparison.
Conclusion
Lymphomas apparently increased among the number of
tumors diagnosed at MNH between 1996 and 2001 fre-
quently appearing related to the HIV epidemic, often pre-
senting early and peaking in young age-groups. The
frequent aggressive clinical and histological presentation
as well as the dominant B-immunophenotype appears
also to suggest an association with HIV and AIDS. Thus,
routine HIV screening of all malignant lymphoma
patients at MNH is necessary in order to allow compre-
hensive ARL determination and formulation of preventive
and therapeutic protocols.
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a) Anti-CD20 (B-cell) antigen immunoperoxidase reactivity in DLBCL; note the granular cytoplasmic reactivity (brown) in all  malignant cells [black arrows] while a macrophage did not stain [blue arrow] (× 200) Figure 5
a) Anti-CD20 (B-cell) antigen immunoperoxidase reactivity in DLBCL; note the granular cytoplasmic reactivity (brown) in all 
malignant cells [black arrows] while a macrophage did not stain [blue arrow] (× 200). (b) Anti-CD3 (T-cell) antigen immu-
noperoxidase reactivity in DLBCL; note the brown focal cytoplasmic reactivity in tumor infiltrating T-lymphocytes [black 
arrows] while the malignant cells were not reactive [blue arrows] (× 400). (c) Anti-CD68 antigen immunoperoxidase reactivity 
in DLBCL; note the brown cytoplasmic reactivity in tumor infiltrating macrophages [black arrow] while malignant cells did not 
stain [blue arrow] (× 400). (d) Anti-Ki-67 (proliferation) antigen immunoperoxidase reactivity in an aggressive lymphoma: note 
the brown granular nuclear reactivity in proliferating cells [black arrows] including the abnormal mitotic bodies [blue arrows] 
(× 400).Journal of Experimental & Clinical Cancer Research 2008, 27:9 http://www.jeccr.com/content/27/1/9
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